Sugi Predict

Sugi Predict / Targets / PTPMT1

PTPMT1

Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 · Q8WUK0 · PTPMT1 on Sugi Atlas →

349 patent compounds predicted against PTPMT1, 283 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL70271 SCHEMBL70271 0.67 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL10982620) 0.65 1/20
SCHEMBL8435278 SCHEMBL8435278 0.61 1/20
SCHEMBL65250 SCHEMBL65250 0.59 1/20
SCHEMBL4407150 SCHEMBL4407150 0.59 1/20
SCHEMBL9051375 SCHEMBL9051375 0.59 1/20
SCHEMBL29563859 SCHEMBL29563859 0.59 1/20
SCHEMBL30638471 SCHEMBL30638471 0.59 1/20
SCHEMBL31336237 SCHEMBL31336237 0.59 1/20
SCHEMBL6586 SCHEMBL6586 0.57 1/20
SCHEMBL80581 SCHEMBL80581 0.57 1/20
SCHEMBL334758 SCHEMBL334758 0.57 1/20
SCHEMBL360723 SCHEMBL360723 0.57 1/20
SCHEMBL456436 SCHEMBL456436 0.57 1/20
SCHEMBL1206832 SCHEMBL1206832 0.57 1/20
SCHEMBL1207329 SCHEMBL1207329 0.57 1/20
SCHEMBL2016247 SCHEMBL2016247 0.57 1/20
SCHEMBL3242805 SCHEMBL3242805 0.57 1/20
SCHEMBL3360788 SCHEMBL3360788 0.57 1/20
SCHEMBL3674500 SCHEMBL3674500 0.57 1/20

Clinical trials — most relevant to PTPMT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy PHASE3UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Structural Network on Prostate Cancer in the French Greater West Region nanCOMPLETED
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome nanCOMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling nanACTIVE_NOT_RECRUITING
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease nanCOMPLETED
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Study of Constitutional Platelet Disease nanUNKNOWN
Pharmacogenetics of Hypertriglyceridemia in Hispanics nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPMT1 binder may also engage these)

ProteinNameSimilarity
Q66GT5 — 1.000 Q66GT5 →
P0C089 — 1.000 P0C089 →
Q86BN8 — 0.997 Q86BN8 →
A1L293 — 0.991 A1L293 →
P0C599 — 0.980 P0C599 →
P0C5A1 — 0.980 P0C5A1 →
A4D256 — 0.979 A4D256 →
P36101 — 0.979 P36101 →
Q6DW73 — 0.979 Q6DW73 →
Q6GQJ8 — 0.978 Q6GQJ8 →
P0C5A0 — 0.978 P0C5A0 →
Q6DW75 — 0.978 Q6DW75 →
Q8TGA1 — 0.978 Q8TGA1 →
C4JF81 — 0.977 C4JF81 →
Q5SNQ7 — 0.977 Q5SNQ7 →
A0A0C1EH92 — 0.977 A0A0C1EH92 →
P00927 — 0.977 P00927 →
Q09509 — 0.977 Q09509 →
Q4WQN1 — 0.977 Q4WQN1 →
G3XNF3 — 0.977 G3XNF3 →
O44997 — 0.977 O44997 →
P40015 — 0.976 P40015 →
Q80YE7 — 0.976 Q80YE7 →
A0A411KZY6 — 0.976 A0A411KZY6 →
Q99N11 — 0.976 Q99N11 →
P50946 — 0.976 P50946 →
DAPK1 Death-associated protein kinase 1 0.976 landscape →
A7XRY0 — 0.976 A7XRY0 →
E9F8M2 — 0.976 E9F8M2 →
Q75B37 — 0.976 Q75B37 →